Biotricity to Showcase Clinical-Grade Remote ECG Monitoring Solution Bioflux at Mobile World Congress 2017

REDWOOD CITY, Calif., Jan. 24, 2017 -- Biotricity Inc. (OTC.QB:BTCY), a healthcare technology company committed to delivering innovative, medically-relevant biometric remote monitoring solutions, will demonstrate its IoT-connected medical device Bioflux, powered by AT&T, at Mobile World Congress (MWC) 2017. One of the biggest annual showcases for connected technology, MWC will be held February 27 — March 3 in Barcelona. Biotricity will showcase how IoT- Connected Healthcare devices can assist in the diagnosis of heart conditions in AT&T’s booth (#4A10).

IDC predicts the global market for IoT will nearly triple, reaching $1.7 trillion by 2020. IoT has long been considered critical to wearable innovation and is becoming more prevalent in the medical space due to its numerous applications. Telecoms are encouraging the adoption of IoT by offering value-add services to help companies, such as Biotricity, go to market with fully connected devices.

“While great progress has been made in the treatment of cardiovascular disease, it is still listed as the underlying cause of the death of more than 800,000 people in the US each year, making it a perfect application for devices that support built-in IoT capabilities,” said Waqaas Al-Siddiq, Biotricity founder and CEO. “Our medical-grade wearable is a superb example of how IoT devices can have a huge impact on healthcare. Bioflux will help diagnose patients by tracking and reporting on cardiac activity in real-time, 24/7. It will also allow physicians to monitor cardiovascular disease, especially arrhythmias, while helping to improve patient outcomes and curbing rising healthcare costs.”

Consisting of an IoT-connected device, ECG-analysis software, and comprehensive remote monitoring center access, Bioflux generates customized reports tailored to a physician's individual patient for diagnostic purposes. Biotricity’s goal is to develop multiple solutions for chronic illnesses by designing monitoring devices paired with chronic care management tools to improve patient compliance and empower the individual to take better care of their health. The Company’s next-generation medical-grade wearables will pave the way for the adoption of preventive care measures into mainstream healthcare practices and help move from the current “reactive” model, where physicians diagnose and treat conditions and diseases after onset, to a proactive one. This is particularly true of managing heart-related illnesses because without any feedback mechanism or continuous monitoring, patients often fail to adhere to doctors’ medical directives, dietary changes, exercise regiments, and lifestyle alterations.

Announced last summer, AT&T will power Biotricity’s wearable medical devices with near real-time connectivity for data transmission. For an up close look at Bioflux while at MWC, visit AT&T’s booth (#4A10), located in the Innovation City.

About Biotricity, Inc.
Biotricity’s mission is to revolutionize chronic care management by developing innovative solutions that bridge the gap between diagnostic care and disease management. A medical technology company, Biotricity is focused on delivering innovative, remote biometric monitoring solutions to the healthcare and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com. 

Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Media Contacts: 
McCoin & Smith Communications Inc.  
Chris McCoin, [email protected], 508-429-5988 
Richard Smith, [email protected], 978-433-3304

Investor Relations: 
Michael Koehler 
Liolios Group, Inc. 
[email protected], 949-574-3860